NASDAQ:BPTHBio-Path Stock Price, Forecast & News

$5.49

-0.01 (-0.18 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$4.87

Now: $5.49▼

$5.79

50-Day Range

$4.58

MA: $5.26▼

$5.90

52-Week Range

$2.92

Now: $5.49▼

$17.53

Volume87,000 shs

Average Volume109,140 shs

Market Capitalization$20.27 million

P/E RatioN/A

Dividend YieldN/A

Beta2.59

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Bio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.00, Bio-Path has a potential upside of 227.9% from its current price of $5.49.
Amount of Analyst Coverage
Bio-Path has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Bio-Path has received 261 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bio-Path has received 223 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bio-Path has received 53.93% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bio-Path and other stocks. Vote “Outperform” if you believe BPTH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BPTH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Bio-Path does not currently pay a dividend.
Dividend Growth
Bio-Path does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bio-Path insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.84% of the stock of Bio-Path is held by insiders.
Percentage Held by Institutions
Only 9.73% of the stock of Bio-Path is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Bio-Path are expected to grow in the coming year, from ($3.77) to ($2.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bio-Path is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bio-Path is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bio-Path has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.49 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:BPTH

Previous Symbol

CUSIPN/A

CIK1133818

Webwww.biopathholdings.com

Phone832-742-1357

Debt

Debt-to-Equity Ratio0.02

Current Ratio12.09

Quick Ratio12.09

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00

Price / Sales506.73

Cash FlowN/A

Price / Cash FlowN/A

Book Value$7.31 per share

Price / Book0.75

Profitability

EPS (Most Recent Fiscal Year)($3.24)

Net Income$-8,600,000.00

Net MarginsN/A

Return on Equity-56.95%

Return on Assets-52.33%

Miscellaneous

Employees8

Outstanding Shares3,692,000

Market Cap$20.27 million

Next Earnings Date8/20/2020 (Estimated)

OptionableNot Optionable

Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

How has Bio-Path's stock been impacted by COVID-19 (Coronavirus)?

Bio-Path's stock was trading at $4.75 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BPTH stock has increased by 15.6% and is now trading at $5.49. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bio-Path?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bio-Path.

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for Bio-Path.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings Inc (NASDAQ:BPTH) released its quarterly earnings results on Friday, May, 15th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.23. View Bio-Path's earnings history.

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Shares of Bio-Path reverse split on the morning of Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for BPTH?

1 analysts have issued 12 month price targets for Bio-Path's stock. Their forecasts range from $18.00 to $18.00. On average, they anticipate Bio-Path's stock price to reach $18.00 in the next year. This suggests a possible upside of 227.9% from the stock's current price. View analysts' price targets for Bio-Path.

What are Wall Street analysts saying about Bio-Path stock?

Here are some recent quotes from research analysts about Bio-Path stock:

1. According to Zacks Investment Research, "BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. " (5/18/2020)
2. HC Wainwright analysts commented, "We believe quarterly operating expenses could approximate $2M in 2H19. The company had $17.1M in cash at the end of June 2019, which should support operations into 2H20. In the wake of this update, we reiterate our Buy rating and $28 price target. Combo trial of prexigebersen + decitabine could report safety data in 2H19. Prexigebersen is an antisense DNA molecule that blocks expression of growth factor receptor-bound protein 2 (Grb-2). Prexigebersen has shown favorable safety and positive Phase 2 interim data in combination with low-dose cytarabine (LDAC) in elderly patients with acute myeloid leukemia (AML), demonstrating 65% objective response with a 29% complete response (CR) rate." (8/16/2019)

Has Bio-Path been receiving favorable news coverage?

Media headlines about BPTH stock have been trending negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bio-Path earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the near term. View the latest news aboutBio-Path.

Who are some of Bio-Path's key competitors?

Some companies that are related to Bio-Path include Synlogic (SYBX), Onconova Therapeutics (ONTX), ContraFect (CFRX), Alpine Immune Sciences (ALPN), Heat Biologics (HTBX), Elite Pharmaceuticals (ELTP), Enlivex Therapeutics (ENLV), DiaMedica Therapeutics (DMAC), Stealth BioTherapeutics (MITO), Moleculin Biotech (MBRX), CannTrust (CNTTF), Trevi Therapeutics (TRVI), Capricor Therapeutics (CAPR), Cassava Sciences (SAVA) and VERONA PHARMA P/S (VRNA). View all competitors.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include Advanced Micro Devices (AMD), Amarin (AMRN), NVIDIA (NVDA), Micron Technology (MU), Anavex Life Sciences (AVXL), Canopy Growth (CGC), TrovaGene (TROV), Agile Therapeutics (AGRX), Energy Transfer LP Unit (ET) and OpGen (OPGN).

Who are Bio-Path's key executives?

Bio-Path's management team includes the following people:

Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 70)
Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 63)
Mr. Anthony Price MBA, Director of Fin. and Accounting
Dr. Alan MacKenzie Ph.D., Consultant
Dr. Thomas A. Walker Ph.D., Consultant

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sabby Management LLC (4.18%) and BlackRock Inc. (1.88%). View institutional ownership trends for Bio-Path.

Which major investors are buying Bio-Path stock?

BPTH stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC, and BlackRock Inc.. View insider buying and selling activity for Bio-Path.

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $5.49.

How big of a company is Bio-Path?

Bio-Path has a market capitalization of $20.27 million and generates $40,000.00 in revenue each year. The company earns $-8,600,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis. Bio-Path employs 8 workers across the globe.

What is Bio-Path's official website?

The official website for Bio-Path is www.biopathholdings.com.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff